Mesenchymal stem cells: Key actors in tumor niche

Current Stem Cell Research and Therapy

Volumn 10, Issue 6, 2015, Pages 523-529

  Marsafy, Sanaa E L ^a   Larghero, Jérôme ^b,c,d  

^a HÔPITAL PAUL BROUSSE   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d INSERM   (France)

Author keywords

Cancer associated fibroblasts; Cancer niche; Cancer stem cells; Cell therapy; Endothelial mesenchymal transition; Epithelial mesenchymal transition; Immune modulation; Mesenchymal stem cells

Indexed keywords

ADAPALENE; BETA CATENIN; CD146 ANTIGEN; CD45 ANTIGEN; CHEMOKINE RECEPTOR CXCR2; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MICRORNA; MICRORNA 16; MICRORNA 23B; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROSTAGLANDIN E2; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SCATTER FACTOR; TENASCIN; THROMBOSPONDIN 1; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER THERAPY; CYTOKINE RELEASE; DNA MODIFICATION; ENDOTHELIAL PROGENITOR CELL; FIBROBLAST; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; MESENCHYMAL STEM CELL; MICROVASCULATURE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TISSUE REGENERATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; UPREGULATION; ANIMAL; EPITHELIAL MESENCHYMAL TRANSITION; IMMUNOLOGY; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; NEOPLASMS; PATHOLOGY; PHYSIOLOGY; STEM CELL NICHE;

ANIMALS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; IMMUNOMODULATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; NEOPLASMS; STEM CELL NICHE; TUMOR MICROENVIRONMENT;

EID: 84947717455     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574888X10666150728121528     Document Type: Article

References (76)

1. Yu Z, Pestell TG, Lisanti MP, Pestell RG. Cancer stem cells. Int J Biochem Cell Biol 2012; 44(12): 2144-51.
2. Cabrera MC, Hollingsworth RE, Hurt EM. Cancer stem cell plasticity and tumor hierarchy. World J Stem Cells 2015; 7(1): 27-36.
3. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells-- perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006; 66(19): 9339-44.
4. Fulawka L, Donizy P, Halon A. Cancer stem cells - the current status of an old concept: literature review and clinical approaches. Biol Res 2014; 47(1): 66.
5. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 1; 100(7): 3983-8.
6. Yagi H, Kitagawa Y. The role of mesenchymal stem cells in cancer development. Front Genet 2013; 4: 261.
7. Long H, Xiang T, Qi W, et al. CD133+ ovarian cancer stem-like cells promote non-stem cancer cell metastasis via CCL5 induced epithelial-mesenchymal transition. Oncotarget 2015; 6(8): 5846-59.
8. Kryczek I, Lin Y, Nagarsheth N, et al. IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity 2014; 40(5): 772-84.
9. Morel AP, Lièvre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelialmesenchymal transition. PLoS One 2008; 3(8): e2888.
10. Krizbai IA, Gasparics Á, Nagyőszi P, Fazakas C, Molnár J, Wilhelm I, Bencs R, Rosivall L, Sebe A. Endothelial-mesenchymal transition of brain endothelial cells: possible role during metastatic extravasation. PLoS One 2015; 10(3): e0119655.
11. Castro-Malaspina H, Gay RE, Resnick G, et al. Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood 1980; 56(2): 289-301.
12. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8(4): 315-7.
13. Miyahara Y, Nagaya N, Kataoka M, et al. Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat Med 2006; 12(4): 459-65.
14. Dezawa M, Ishikawa H, Itokazu Y, et al. Bone marrow stromal cells generate muscle cells and repair muscle degeneration. Science 2005; 309(5732): 314-7.
15. EL Marsafy S, Larghero J, Bennaceur-Griscelli A, Turhan A. Mesenchymal stem cells: pivotal players in hematopoietic stem cell microenvironment. J Stem Cell Res Ther 2014; 4: 8.
16. Nwajei F, Konopleva M.The bone marrow microenvironment as niche retreats for hematopoietic and leukemic stem cells. Adv Hematol 2013; 2013: 953982.
17. Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res 2011; 109(8): 923-40.
18. Valle-Prieto A, Conget PA. Human mesenchymal stem cells efficiently manage oxidative stress. Stem Cells Dev 2010; 19(12): 1885-93.
19. Pasquier J, Rafii A. Role of the microenvironment in ovarian cancer stem cell maintenance. Biomed Res Int 2013; 2013: 630782.
20. Devine SM, Cobbs C, Jennings M, Bartholomew A, Hoffman R. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003; 101(8): 2999-3001.
21. Rüster B, Göttig S, Ludwig RJ, et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 2006; 108(12): 3938-44.
22. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. A new mesenchymal stem cell (MSC) paradigm: polarization into a proinflammatory MSC1or an Immunosuppressive MSC2 phenotype. PLoS One 2010; 5(4): e10088.
23. Yagi H, Kitagawa Y. The role of mesenchymal stem cells in cancer development.Front Genet 2013; 4: 261.
24. Zhu Y, Sun Z, Han Q, et al. Human mesenchymal stem cells inhibit cancer cell proliferation by secreting DKK-1. Leukemia 2009; 23(5): 925-33.
25. Qiao L, Xu ZL, Zhao TJ, Ye LH, Zhang XD. Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Cancer Lett 2008; 269(1): 67-77.
26. Wang J, Bian C, Liao L, et al. Inhibition of hepatic stellate cells proliferation by mesenchymal stem cells and the possible mechanisms. Hepatol Res 2009; 39(12): 1219-28.
27. Khakoo AY, Pati S, Anderson SA, et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med 2006; 203(5): 1235-47.
28. Barcellos-de-Souza P, Gori V, Bambi F, Chiarugi P.Tumor microenvironment: bone marrow-mesenchymal stem cells as key players. Biochim Biophys Acta 2013; 1836(2): 321-35.
29. Yu B, Zhang X, Li X. Exosomes derived from mesenchymal stem cells. Int J Mol Sci 2014; 15(3): 4142-57.
30. Lee JK, Park SR, Jung BK, et al. Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulatingVEGF expression in breast cancer cells. PLoS One 2013; 8(12): e84256.
31. Zhu W, Huang L, Li Y, et al. Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo. Cancer Lett 2012; 315(1): 28-37.
32. Augsten M. Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment. Front Oncol 2014; 4: 62.
33. Touboul C, Vidal F, Pasquier J, Lis R, Rafii A. Role of mesenchymal cells in the natural history of ovarian cancer: a review. J Transl Med 2014; 12(1): 271.
34. Chowdhury R, Webber JP, Gurney M, Mason MD, Tabi Z, Clayton A. Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts. Oncotarget 2015; 6(2): 715-31.
35. Suzuki K, Sun R, Origuchi M, et al. Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization. Mol Med 2011; 17(7-8): 579-87.
36. Bexell D, Gunnarsson S, Tormin A, et al. Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol Ther 2009; 17(1): 183-90.
37. Vermeulen L, De Sousa E Melo F, van der Heijden M, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010; 12(5): 468-76.
38. Sidibé A, Imhof BA. 5'-Ectonucleotidase/CD73 expression on lymph-circulating lymphocytes and lymphatic endothelial cells offers new paths to explore barrier function. Eur J Immunol 2015; 45(2): 371-5.
39. Lee JJ, Jeong HJ, Kim MK, et al. CD39-mediated effect of human bone marrow-derived mesenchymal stem cells on the human Th17 cell function. Purinergic Signal 2014; 10(2): 357-65.
40. Poggi A, Musso A, Dapino I, Zocchi MR. Mechanisms of tumor escape from immune system: role of mesenchymal stromal cells. Immunol Lett 2014; 159(1-2): 55-72.
41. Mokarizadeh A, Delirezh N, Morshedi A, Mosayebi G, Farshid AA, Mardani K. Microvesicles derived from mesenchymal stem cells: potent organelles for induction of tolerogenic signaling. Immunol Lett.2012; 147(1-2): 47-54.
42. Chanmee T, Ontong P, Konno K, Itano N. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel) 2014; 6(3): 1670-90.
43. Alfano M, Graziano F, Genovese L, Poli G. Macrophage polarization at the crossroad between HIV-1 infection and cancer development. Arterioscler Thromb Vasc Biol 2013; 33(6): 1145-52.
44. Standiford TJ, Kuick R, Bhan U, Chen J, Newstead M, Keshamouni VG. TGF-β-induced IRAK-M expression in tumorassociated macrophages regulates lung tumor growth. Oncogene 2011; 30(21): 2475-84.
45. Roccaro AM, Sacco A, Maiso P, et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest 2013; 123(4): 1542-55. Erratum in: J Clin Invest 2013; 123(8): 3635.
46. Ono M, Kosaka N, Tominaga N, et al. Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells. Sci Signal 2014; 7(332): ra63.
47. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006; 107(4): 1484-90.
48. Selmani Z, Naji A, Zidi I, et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008; 26(1): 212-22.
49. Zhang B, Yin Y, Lai RC, Tan SS, Choo AB, Lim SK. Mesenchymal stem cells secrete immunologically active exosomes. Stem Cells Dev 2014; 23(11): 1233-44.
50. Lee JH, Jeon EJ, Kim N, et al. The synergistic immunoregulatory effects of culture-expanded mesenchymal stromal cells and CD4(+)25(+)Foxp3+ regulatory T cells on skin allograft rejection. PLoS One 2013; 8(8): e70968.
51. Gu JJ, Gao GZ, Zhang SM. miR-218 inhibits the migration and invasion of glioma U87 cells through the Slit2-Robo1 pathway. Oncol Lett 2015; 9(4): 1561-66.
52. Chen WF, Gao WD, Li QL, Zhou PH, Xu MD, Yao LQ. SLIT2 inhibits cell migration in colorectal cancer through the AKTGSK3β signaling pathway. Int J Colorectal Dis 2013; 28(7): 933- 40.
53. Kudo-Saito C, Yura M, Yamamoto R, Kawakami Y. Induction of immunoregulatory CD271+ cells by metastatic tumor cells that express human endogenous retrovirus H. Cancer Res 2014; 74(5): 1361-70.
54. Kudo-Saito C. FSTL1 promotes bone metastasis by causing immune dysfunction. Oncoimmunology 2013; 2(11): e26528.
55. Kudo-Saito C. Cancer-associated mesenchymal stem cells aggravate tumor progression. Front Cell Dev Biol 2015; 3: 23.
56. Li HJ, Reinhardt F, Herschman HR, Weinberg RA.Cancerstimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discov 2012; 2(9): 840-855.
57. Maitland NJ. Carcinoma-derived exosomes modify microenvironment. Oncotarget 2015; 6(3): 1344-45.
58. Li P, Yang R, Gao WQ. Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer. Mol Cancer 2014; 13: 55.
59. van de Stolpe A. On the origin and destination of cancer stem cells: a conceptual evaluation. Am J Cancer Res 2013; 3(1): 107-16.
60. Ghiabi P, Jiang J, Pasquier J, et al. Breast cancer cells promote a notch-dependent mesenchymal phenotype in endothelial cells participating to a pro-tumoral niche. J Transl Med 2015; 13(1): 27.
61. Noseda M, McLean G, Niessen K, et al. Notch activation results in phenotypic and functional changes consistent with endothelial-tomesenchymal transformation. Circ Res 2004; 94(7): 910-17.
62. Krizbai IA, Gasparics Á, Nagyőszi P, et al. Endothelialmesenchymal transition of brain endothelial cells: possible role during metastatic extravasation. PLoS One 2015; 10(3): e0119655.
63. Duda DG, Jain RK. Premetastatic lung "niche": is vascular endothelial growth factor receptor 1 activation required? Cancer Res 2010; 70(14): 5670-3.
64. Halpern JL, Kilbarger A, Lynch CC. Mesenchymal stem cells promote mammary cancer cell migration in vitro via the CXCR2 receptor. Cancer Lett 2011; 308(1): 91-9.
65. Schuettpelz LG, Link DC. Niche competition and cancer metastasis to bone. J Clin Invest 2011; 121(4): 1253-55.
66. Amé-Thomas P, Maby-El Hajjami H, Monvoisin C, et al. Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. Blood 2007; 109(2): 693-702.
67. Rodríguez R, García-Castro J, Trigueros C, García Arranz M, Menéndez P. Multipotent mesenchymal stromal cells: clinical applications and cancer modeling. Adv Exp Med Biol 2012; 741: 187-205.
68. Bak XY, Dang HL, Yang J, Ye K, et al. Human Embryonic Stem Cell-derived Mesenchymal Stem Cells as Cellular Delivery Vehicles for Prodrug Gene Therapy of Glioblastoma. Hum Gene Ther 2011; 22(11): 1365-77.
69. Birnbaum T, Roider J, Schankin CJ, et al. Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. J Neurooncol 2007; 83(3): 241-7.
70. Micheau O, Shirley S, Dufour F. Death receptors as targets in cancer. Br J Pharmacol 2013; 169(8): 1723-44.
71. Luetzkendorf J, Mueller LP, Mueller T, Caysa H, Nerger K, Schmoll HJ. Growth inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal stem cells requires their substantial intratumoral presence. J Cell Mol Med 2010; 14(9): 2292-304.
72. Law S, Chaudhuri S. Mesenchymal stem cell and regenerative medicine: regeneration versus immunomodulatory challenges. Am J Stem Cells 2013; 2(1): 22-38.
73. Xin H, Sun R, Kanehira M, et al. Intratracheal delivery of CX3CL1-expressing mesenchymal stem cells to multiple lung tumors. Mol Med 2009; 15(9-10): 321-7.
74. Ohta N, Ishiguro S, Kawabata A, et al. Human umbilical cord matrix mesenchymal stem cells suppress the growth of breast cancer by expression of tumor suppressor genes. PLoS One 2015; 10(5): e0123756.
75. Kim JH, Lee HJ, Song YS. Stem cell based gene therapy in prostate cancer. Biomed Res Int 2014; 2014: 549136.
76. Niess H, von Einem JC, Thomas MN, et al. Treatment of advanced gastrointestinal tumors with genetically modified autologous mesenchymal stromal cells (TREAT-ME1): study protocol of a phase I/II clinical trial. BMC Cancer 2015; 15: 237.